drug eruptions, author unknown
TRANSCRIPT
Rotator Lecture VI
Drug Eruptions, CTD, NF, MF
Exanthematous Drug Eruptions
• Most common manifestation of drug reactions
• Presents as erythematous macules and papules coalescing into diffuse erythema
• Skin may peel as rash is resolving
• Most common causes include sulfa, PCN, and PCN derivatives
Figure 23.1 Exanthematous drug eruptions. Numerous pink papules on the trunk due to a cephalosporin (A). Confluence of lesions on
the trunk (B) and annular plaques on the forehead (C) secondary to phenobarbital.
Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
Figure 23.1 Exanthematous drug eruptions. Numerous pink papules on the trunk due to a cephalosporin (A). Confluence of lesions on
the trunk (B) and annular plaques on the forehead (C) secondary to phenobarbital.
Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
Usually worst on LE due to orthostatic pressure.
Fixed Drug Eruption• Occurs in the same place each time a
patient is challenged with a particular drug
• Round or oval lesion with an ash gray to slate blue colored center, may have bullae
• Can have 1 lesion or multiple
• Common causes include laxatives, NSAIDs, sulfa drugs, tetracyclines
Figure 23.11 Fixed drug eruptions. Well-demarcated erythematous (A) to violet-brown plaques that can develop a detached epidermis
Responsible drug was phenophthalein (A)
Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
Erythema Multiforme (EM)
• This has many causes, drug eruption is one etiology
• Erythematous target-like lesions• Minor variant does not require
hospitalization– Usually a reaction to HSV infection
• Major variant (Stevens-Johnson) requires hospitalization and immediate treatment
Figure 21.1 Phenotypic variety in EM. D classic target lesions on the palms.
Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
Stevens Johnsons Syndrome (SJS) and Toxic Epidermal Necrosis
(TEN)
• SJS and TEN always caused by a drug• More severe than EM• Involves mucosa• SJS arbitrarily defined as involving at least 2
mucous membranes and having at least 10% body surface area involved
• TEN is worst end of spectrum with more severe cutaneous and mucosal manifestations and can be fatal
SJS and TEN
• Common causes include antiepileptics, sulfa drugs• More severe than EM• SJS: Rapid course, large sheets of necrotic skin,
can involve mucosa, evolves within days; can rapidly turn into TEN (hrs)
• TEN: Extremely rapid course. Evolves within hours. Can be fatal! Treat patient in burn unit, administer IV Ig, plasma pheresis
• Oral/systemic steroids have not been able improve mortality (can increase susceptibility to infection)
Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
Figure 21.6 Denuded and crusted lesions of the lips with minimal cutaneous lesions in a child with SJS secondary to antibiotic
therapy.Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
Figure 21.7 Severe conjunctival erosions and exudate in SJS secondary to trimethoprim-sulfamethoxazole therapy.
Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
Figure 22.6 Stevens-Johnson syndrome (SJS) versus SJS-TEN overlap. In addition to mucosal involvement and widespread erythematous papules, there are small areas of epidermal
detachment (arrows). Because the latter involve 10% body surface area, the patient is classified as having SJS.Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
Figure 22.5 Clinical features of toxic epidermal necrolysis (TEN). A Detachment of large sheets of necrolytic epidermis (>30% body
surface area), leading to extensive areas of denuded skin. B Hemorrhagic crusts with mucosal involvement. C Epidermal
detachment of palmar skin.Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
Figure 22.4 Cutaneous features of toxic epidermal necrolysis (TEN). A Characteristic dusky-red color of the early macular
eruption in TEN. Lesions with this color often progress to full-blown necrolytic lesions with dermo-epidermal detachment. B Positive Nikolsky sign: epidermal detachment reproduced by mechanical
pressure on an area of erythematous skin.Downloaded from: Dermatology (on 29 June 2006 07:55 PM)
© 2005 Elsevier
TEN
Urticaria
• Has many causes! Pressure, exercise, food, temperature, and drug
• Transient lesion (<24 hours), new ones can form with continued contact
• Resolve without scarring
• Remove offending agent(s), administer anti-histamines
Angioedema
• severe form of urticaria involving dermis and subcutaneous swelling which can affect airway, mucosa, and bowels.
• Can be from food, medication, latex allergy
Angioedema
• Can occur simultaneously with urticaria
• Angioedema without urticaria can also occur– Drug reaction– C1 esterase inhibitor
deficiency
JAAD 2002; 46: 645-57.
Angioedema: Drug Reactions
ACE Inhibitors • Often orofacial angioedema• Urticaria/angioedema is believed to result
from the inhibition of endogenous kininase• Can occur up to 1 yr after starting med
NSAIDs
Aspirin
Angioedema: Drug ReactionsManagement
• Withdrawal of drug
• Antihistamines, corticosteroids
• Epinephrine may be needed if airway in trouble or very severe
• Report of FFP used in refractory case (to above and IVIg, CSA)
Hereditary Angioedema• Autosomal dominant; with incomplete penetrance• 1:150,000• Mutations in one copy of the gene for C1 inhibitor
– Type 1: reduced levels of C1 inh (85% of cases)
– Type 2: functionally deficient C1 inh (15% of cases)
• C1inh deficiency allows activation of the C1 – generation of bradykinin
– subsequent consumption of complement leads to low levels of C4 in the serum
Hereditary Angioedema
• Trauma can precipitate attacks
• Attacks last 48-72 hrs– Laryngeal edema– Abdominal pain
• NO WHEALS (ie NO URTICARIA)
Hereditary Angioedema
Fitz 6th ed p 1132
Acquired Angioedema
Type 1• C1 fixed by anti-idiotypic antibodies causes
consumption of C1 inh– Seen in lymphoproliferative disease, esp.
multiple myeloma, Waldenstroms, B cell lymphoma, CLL
Type 2• autoantibodies (IgG1) against C1 inh
– Associated with SLE, RA, Sjogren’s
Angioedema (only) work-up• Medications:
– Avoid estrogens
• FH• C4 : BEST SCREEN
– Screens both hereditary and acquired C1 inhibitory deficiency
• C1q– Low in acquired C1 inh def.
• C1 inh assay– Amount: type 1 deficiency
– Function: type 2 deficiency
Hereditary Angioedema: Rx
• C1 inh concentrate of FFP– For emergencies
• Tranexamic acid (IV)– FDA approved for hemophilia– antifibrinolytic agent: competitively inhibits the
activation of plasminogen to plasmin
• Danazol, Stanozolol: treatment of choice
Acquired Angioedema: Rx
• Secondary to lymphoproliferative disease– Stanozolol– Danazol
• Secondary to anti-C1Inh autoantibodies– Respond to glucocorticoids
Dermatomyositis• Combination of skin and striated muscle
inflammation• Characteristic Skin Manifestations:
– Heliotrope Rash – Gottron’s papules/sign– Poikiloderma (atrophy, telangectasia, and pigmentary
alteration)
• Muscle Manifestations– Symmetric proximal muscle weakness– Elevation of skeletal muscle enzymes (CPK, aldolase)– EMG, muscle biopsy, and MRI can also be used to
confirm myositis
Heliotrope: periorbital edema with a lightly violaceous hue
Gottron’s Papules
• Pathogmonic for Dermatomyositis• Erythematous-violaceous scaly papules
over dorsal IP joints, elbows, or knees• Gottron’s sign are patches or plaques of the
same color in the same distribution• Photosensitivity is the proposed etiology• Associated with proximal nail fold atrophy
and telangiectasia
Gottron’s papules
Figure 44.4 Gottron's sign with violaceous poikiloderma over the knuckles.
Downloaded from: Dermatology (on 29 June 2006 08:28 PM)
© 2005 Elsevier
Figure 44.2 Violaceous poikiloderma of the face, plus thin plaques on the elbows (Gottron’s sign) that are sometimes misdiagnosed as
psoriasis.Downloaded from: Dermatology (on 29 June 2006 09:20 PM)
© 2005 Elsevier
Figure 44.1 Violaceous poikiloderma of the face. Heliotrope also noted.
Downloaded from: Dermatology (on 29 June 2006 09:20 PM)
© 2005 Elsevier
Dermatomyositis
• Up to 25% are associated with underlying malignancy
• Ovarian cancer is overrepresented in women
• Patient’s with new diagnosis need cancer screening at diagnosis and yearly
Scleroderma
• Disorder characterized by fibrosis of connective tissue, increased collagen deposition, and vascular alterations.
• Localized disease without systemic manifestations is called “morphea” or “localized scleroderma”
• Systemic disease with skin manifestations is called “systemic scleroderma”– Subsets of this are CREST and systemic sclerosis
• ANA is not helpful in diagnosis
Localized form of morphea: ‘en coup de sabre’
Limited Systemic Sclerosis: CREST
Sclerodactyly seen in CREST
Figure 45.3 Mat telangiectasias in a patient with systemic sclerosis (scleroderma).
Downloaded from: Dermatology (on 29 June 2006 08:28 PM)
© 2005 Elsevier
Progressive Systemic Sclerosis
• Skin thickening is more widespread and proximal
• Can be severe and rapidly fatal
• Both CREST and PSS can causes renal disease and pulmonary sclerosis
Cutaneous Lupus
• ACUTE: Typical photosensitive malar rash when acute– Highly associated with systemic LE (almost
100%)
• SUBACUTE: This variant is psoriasiform or papulosquamous– ~50% of these patients will meet criteria for
SLE
• CHRONIC: ie Discoid Lupus– Most patients (85-90% never develop systemic
lupus)
Figure 43.4 Acute cutaneous lupus (ACLE) lesions in a butterfly distribution on the face of a young woman. Note sparing of
nasolabial folds.Downloaded from: Dermatology (on 29 June 2006 08:28 PM)
© 2005 Elsevier
Figure 43.5 Acute cutaneous lupus (ACLE). The patient shown in this photo had ACLE lesions on the arms as well as the face.
Downloaded from: Dermatology (on 29 June 2006 08:28 PM)
© 2005 Elsevier
Figure 43.7 Subacute cutaneous lupus (SCLE) lesions of the sun-exposed aspects of the upper arm. Note the annular configuration
and crusting of the borders. Downloaded from: Dermatology (on 29 June 2006 08:28 PM)
© 2005 Elsevier
Discoid Lupus Erythematous (DLE)
• Most scarring and chronic form of cutaneous lupus
• Discoid shaped plaques with white scale, with time, lesions become atrophic
• Can lead to scarring alopecia• Few patients meet criteria for SLE• Treat with intralesional or topical steroids, sun
avoidance, plaquenil if severe or large areas involved
Figure 43.9 Chronic cutaneous lupus erythematosus (CCLE) with discoid lesions. The ear is a common site of involvement. Note the central depigmentation, scarring and peripheral hyperpigmentation.
Downloaded from: Dermatology (on 29 June 2006 08:28 PM)
© 2005 Elsevier
Figure 43.10 Chronic cutaneous lupus erythematosus (CCLE) discoid lesion.
Downloaded from: Dermatology (on 29 June 2006 08:28 PM)
© 2005 Elsevier
Neurofibromatosis • Type 1 (vonRecklinghousen) is more common that
Type 2• Autosomal dominant inheritance in half of cases,
other half are spontaneous• Hereditary form has variable penetrance; can be
associated with mental retardation • Some Criteria: 2 or more neurofibromas, 6 or
more café au lait macules, Lisch nodules in the eyes, Axillary or inguinal freckles (Crows sign)
Mycosis Fungoides (MF)
• Most common type of cutaneous T-cell lymphoma
• NOT A FUNGAL DISEASE!• Most common in middle-aged white men• Occurs in patch and plaque stages • Asymmetrical distribution of lesions • Treat with steroids, UVB, nitrogen mustard,
PUVA, methotrexate, retinoids, interferons
Patch vs. Plaque Stages of MF
• Flat• Fine white scale• Erythematous • ‘Cigarette paper’
wrinkling• Serpiginous or annular• Non-specific rash, can
resemble psoriasis or eczema
• Localized
• Red to violaceous nodules
• Associated with lymphadenopathy
• Alopecia
• Hyperkeratosis of palms and soles
• Widespread
• Lesions can become ulcerated
Thank You!